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The National Institute of Clinical Excellence (NICE) has
three main roles. It provides guidance to the National
Health Service (NHS) on the use of selected new and ex-
isting technologies (the appraisal process), provides clini-
cal guidelines for clinicians and physicians in important
treatment areas, and develops audit methodologies. This
paper discusses the NICE appraisal process. The specific
steps of the appraisal process are described, including the
basis for topic selection. An overview of NICE guidelines
for manufacturers and sponsors is reported. First-year
experience is assessed, reflecting on the quality of sub-
mitted evidence, and the content of the forthcoming pro-
gram is presented. Finally, the impact of NICE appraisals
is explored in terms of potential benefits and risks.
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Introduction
 
The National Institute for Clinical Excellence (NICE)
is a special Health Authority that came into being on
April 1, 1999. Its role is to make recommendations to
National Health Service (NHS) clinicians and manag-
ers in England and Wales on the use of selected new
and existing health technologies, to produce clinical
guidelines, and to develop audit methodologies. A
number of health care technologies have already
been evaluated through the NICE appraisal process
and subsequent guidance to the NHS has been issued.
NICE recommendations have fueled considerable de-
bate in the international health care community. This
paper discusses activities and implications of the
NICE work program, specifically the appraisal pro-
cess for new and existing health technologies.
 
The National Institute Of Clinical Excellence 
and the Appraisal Process
 
The National Institute of Clinical Excellence was
set up with three main responsibilities:
1. appraisal of new and existing technologies;
2. development of clinical guidelines that are fo-
cused on patient groups or disease areas; and
3. development of audit methodologies.
The appraisal process includes a number of steps
(Fig. 1). The first step involves horizon scanning of
new technologies, a process contracted to an aca-
demic research group at the University of Birming-
ham. This information is given to the Department
of Health, where a committee advises ministers
who decide on priorities for the technologies that
NICE should appraise. Topics are selected based
on their potential to have significant impact in terms
of health benefits, health policies or resources, and
on NICE’s ability to add value by reducing contro-
versy. This process of topic selection is under review
and a revised process will be published in the near
future. Technology assessment reports are then
commissioned by NICE from independent academic
groups; submissions are also sought from manufac-
turers and other interested parties, including organi-
zations that represent patients. Once these documents
are available, an appraisal is made by a multidisci-
plinary appraisal committee, which reviews submit-
ted evidence and issues a Provisional Appraisal Deter-
mination. The Provisional Appraisal Determination
is then communicated back to the interested par-
ties for comment. The NICE Committee subse-
quently reviews any comments received and a Final
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Appraisal Determination is made. NICE allows op-
portunity for appeal from any of the interested
parties before making final recommendations and
issuing guidance to the NHS.
The Secretary of State for Health has indicated
that six factors should be taken into account by
NICE in its appraisal process. These are:
• broad clinical priorities for the NHS;
• degree of clinical need of patients with the con-
dition;
• broad balance of benefits and costs (cost-effec-
tiveness);
• guidance on resources likely to be available;
• effective use of available resources; and the en-
couragement of innovation.
Only a relatively small selection of high-impact
technologies can be appraised: current planning is
for approximately 50 per year. The appraisal process
often considers a group, class, or a generic health
technology, within which NICE may choose not to
make differential recommendations.
 
Nice Guidelines for Manufacturers and Sponsors
 
Guidelines for manufacturers and sponsors sub-
mitting evidence were published by NICE in Sep-
tember 1999 with regard to clinical effectiveness,
cost-effectiveness, and wider NHS implications [1].
These guidelines are currently under revision, and
a number of issues have arisen. Should the guide-
lines be in the format of a recipe or simply a state-
ment of principles, and what degree of flexibility
should be allowed?
These points are particularly important because
NICE not only assesses new technologies but also
existing ones, and it covers drugs, devices and pro-
cedures. Furthermore, because NICE works within
an international context, its methods of examining
evidence need to assist broader compatibility of
evidence.
The revised draft guidelines recommend per-
forming economic evaluations from the perspec-
tive of the decision maker whose concern is to
maximize benefits from the NHS and the Personal
Social Service budgets (the latter covers much of
the cost of supporting ill or elderly persons in their
own homes or communities). This implies that clin-
ical and health-related benefits as valued by soci-
ety should be included with costs to the NHS and
to the Personal Social Services. Cost-effectiveness or
cost-utility analyses are preferred, the principle com-
parator being the most commonly used alternative,
together with any more cost-effective comparators
when available. Clinical outcomes of interest include
morbidity, mortality, and patient assessment of qual-
ity of life at appropriate time points, linked to data
on social preferences for use in cost-utility analysis.
In assessing these outcomes, it is important to con-
sider where the greatest benefit lies and which pa-
tients are the most appropriate to treat. In translat-
ing evidence on patient quality of life into cost utility
analysis, NICE considers the most relevant utilities
to be those pertaining to the UK population. Impact
on social productivity should also be assessed if rele-
vant, but not incorporated into cost-effectiveness or
cost-utility ratios.
The key implications of such analyses are that: 1)
economic evaluations should address competing uses
of the health service budget; and 2) a principle aim is
the maximization of quality-adjusted life years within
a fixed budget. The guidelines acknowledge that ideal
data may not be available and that modeling is al-
most inevitable for assessment of long-term impact.
 
Past and Future Appraisals
 
The initial scope of NICE assessment included five
areas covering pharmaceuticals, medical devices,
diagnostics and screening, procedures, and health
promotion. So far, referrals to NICE have concen-
trated on pharmaceutical and medical device as-
sessments and the focus of future appraisals that have
been announced is primarily on new drugs (Table 1).
The immediate forthcoming program focuses pre-
dominantly on cancer-related pharmaceuticals, re-
flecting an NHS priority on cancer. Selection of tech-
nologies is in itself controversial, and controversy
surrounds the technologies as well. Although the
current focus is on new drugs, it is important that
NICE should also examine established technolo-
gies and identify areas where existing use of health
care resources might appropriately be reduced.
Figure 1 The NICE appraisal process. DoH, Department of
Health Committee; NAW, National Assembly for Wales;
AD, Appraisal Determination.
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During its first 12 months of operation, NICE
has received evidence of variable quality, although
improvement has been noted. With respect to cost-
effectiveness analyses, the principle weakness lies
within the clinical data. Clinical data may be very
solid for 3 or 6 months but lacking for the longer
term, or it may be solid for a particular group of
patients included in a clinical trial but difficult to
extrapolate to broader patient populations, or it
may be difficult to identify subgroups of patients
within trials who would benefit most from the
technology. In many instances, useful Quality Ad-
justed Life Year (QALY) information has been
lacking. There is usually a need for modeling stud-
ies to extrapolate data beyond clinical trial data,
which has created some difficulties because of the
lack of transparency in many existing models.
A variety of sources of cost-effectiveness evidence
have been received, including studies performed in-
house by manufacturers and studies performed by
consulting groups or academics for industry, some
of which have been published. The Committee has
learned to make no presumptions of superiority of ev-
idence based on source. The Committee experienced
difficulty trying to appropriately reflect and synthesize
the vast amount of evidence that was provided by the
various stakeholders, ranging from formal meta-anal-
yses to economic modeling studies and important but
narrative histories of patient experiences.
Certain common features can be deduced from
the appraisals conducted to date. NICE guidance
aims to identify groups of patients who will bene-
fit most or who will produce the best cost-effec-
tiveness ratio; this can be difficult given the weak-
ness of some of the evidence provided. Guidance
aims to provide brief justifications for conclusions
made. It also recognizes the need to revisit conclu-
sions when new evidence comes to light. NICE
makes no explicit statement of the upper limit of
acceptable cost per QALY; it is believed that a sin-
gle threshold would not be appropriate given the
multiple criteria it uses.
 
The Impact of NICE Appraisals
 
The hope is that NICE appraisals will lead to clar-
ity and consistency within the NHS concerning key
technologies and will help eliminate postcode ra-
tioning whereby each health authority makes its
own, and often differing, decision on availability of
health technologies. Appraisals legitimize and em-
phasize cost-effectiveness criteria and highlight the
importance of cost-effectiveness data for developers
of technology. More speculatively, it is hoped that
NICE appraisals will also create public debate since
it appears that there is little public understanding or
discussion about health economic issues.
There are two possible types of error associated
with early assessment of technologies such as the
NICE appraisal process. A type 1 error may occur
if NICE recommends a technology as cost-effective
that in reality is not. This may be harmful for cer-
tain patients, and since it is recommended by NICE,
there is likely to be a diffusion of the technology
with an opportunity cost to the health system. Once
the technology has been diffused, difficulty would
then exist in restricting its use if the error were
later identified. While there is agreement that NICE
should revisit technologies, the reality of the NHS
means that it may be difficult to subsequently cease to
provide a technology on cost-effectiveness grounds.
Type 2 errors may occur when NICE concludes that a
technology is not cost-effective, but in reality it is or
might prove to be with further evidence. This er-
ror would likely prevent or limit diffusion and
NHS resources would be devoted to other technol-
ogies. Also, the producer may suffer from a loss of
market, and appropriate patient groups will not
have access to a cost-effective product. This type of
error raises the issue of importance of early identi-
fication of the best application of technologies and
of the most appropriate patient groups.
Within these risks, certain asymmetries exist.
Imbalance between the magnitudes of risk from
type 1 and type 2 errors depends on the degree of
the Appraisal Committee’s caution. If the commit-
tee recommends a technology about which it has
doubts, there is greater risk of type 1 error; if it is
very cautious in its recommendations, there is greater
risk of type 2 error. Asymmetry may also stem
 
Table 1
 
Range of technologies assessment covered 
by NICE
 
Technology Guidance issued* Guidance announced
 
†
 
Pharmaceuticals 7
 
‡
 
15
Medical devices 5
 
§
 
0
Diagnostic/screening 1
 

 
0
Procedures 1
 
¶
 
3
Health promotion 0 0
 
*As of October 30, 2000.
 
†
 
All other topics up to and including Third Wave Program.
 
‡
 
Zanamavir, taxanes for ovarian cancer and breast cancer, proton pump inhibi-
tors in dyspepsia treatment, roziglitazone for type II diabetes, glycoprotein
11b/111a inhibitors in treatment of acute coronary syndromes, methylpheni-
date for ADHD, ribavarin and interferon alpha for Hepatitis C.
 
§
 
Selection of prostheses for primary total hip replacement, coronary artery
stents for Ischemic heart disease, hearing aid technology, inhaler systems for
children 
 

 
5 years with chronic asthma, implantable cardioverter defibrillators
for arrhythmias.
 

 
ALiquid based cytology for cervical screening.
 
¶
 
Removal of wisdom teeth.
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from the valuation of risk in clinical outcome and
cost-effectiveness outcome (i.e., relative effective-
ness vs. genuine cost-effectiveness). Finally, there
is asymmetry between risks to particular stake-
holders; namely patients, the general population,
the health system, and producers of technology.
The balance of these risks will need to be kept un-
der review as experience develops.
 
Conclusion
 
The actions of the NICE Appraisal Committee
raise a number of questions:
• Does NICE appraise a sensible range of tech-
nologies?
• Have the appraisals been relatively robust?
• Have the technology proponents accepted an
honest attempt at a rational process?
• Does the NHS follow NICE advice?
• Will ministers balk when they realize their in-
ability to disassociate themselves from the dif-
ficult recommendations made by NICE?
• Will public opinion be behind NICE?
Answers to these questions will help evaluate the
success of NICE. For all parties involved, it has been
and continues to be a steep learning curve. Although
progress and positive signs have been noted, the ver-
dict concerning overall impact of NICE is not yet
cast.
 
Question Period
 
Unidentified Speaker # 1
 
We in the Netherlands have recently seen the eval-
uation of statins and influenza vaccine, where
more or less implicitly the threshold was at 30,000
guilders per life year gained, which is US$15,000
per life year gained. Do you think this is where we
are heading, this threshold? Will this threshold
that is now evaluated for preventive services be
the same for curative applications of drugs?
 
M. Buxton
 
There are two sets of issues. One is that it is not
simple, even if we were only concerned with cost-
effectiveness. It is not as easy as talking about the
mean cost-effectiveness or cost per QALY—clearly
there are issues about the distribution of the un-
certainty around that mean. The major concern
pertains to uncertainty about magnitudes of both
parts of the ratio. Even if decisions were based solely
on cost-effectiveness data, it would be difficult to
select a single threshold. Most importantly, from
the UK perspective, other factors besides cost-effec-
tiveness data have to be taken into account. Clearly,
if a single threshold were used, it would imply that
no other factors are considered. The NICE appraisal
process needs some flexibility and there is no hid-
den single value.
 
Unidentified Speaker #2
 
Whether or not the ultimate decision is based on
cost-effectiveness or other factors, organizations
seem to think that the right thing to do is make a
national decision and try to avoid postcode prescrib-
ing and allocation. If this is the agenda, maybe we
should just get rid of all regional health authorities
because their only 
 
raison d’être
 
 is to make local
decisions, which take into account geography, re-
source availability, and possibly genuine local vari-
ations in populations. Are you handing down guid-
ance which people are expected to adapt locally?
Are you going to give local authorities models allow-
ing them to work out cost-effectiveness in their patch
or are you trying to produce a national steer that this
technology should either be adopted or not?
 
M. Buxton
 
It is fairly clear that NICE is trying to give a na-
tional steer that reflects a real concern about post-
code prescribing. It is not expected though that
things will be absolutely identical everywhere. I
agree with you about the first point you made, but
the reality is that most countries have systems where
components are not totally logical and consistent.
NICE is not planning to steer everything but rather
to facilitate more national consistency on a number
of high-profile and important issues.
 
S. Klang, Clalit Health Services, Tel Aviv, Israel
 
How can you control the use of a given drug? We
have the same problem with certain drugs which
are not reimbursed. We have seen that just writing
guidelines is not enough to control use or con-
sumption of a drug or to limit its use to a small
group of patients.
 
M. Buxton
 
The budget impact is not an independent criterion
and NICE generally examines cost-effectiveness
data; however, it is important to consider budget
impact especially for technology that may have a
massive impact on the health care system. With re-
gard to threshold, the ranking of technologies should
not change, but if new data indicate a major change
in application, it might indeed change its ranking
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among other technologies. It is a very complex sys-
tem. Working from first principles within a fixed
budget would mean that each time a new technol-
ogy is included, the ranking of all technologies
should be reviewed. NICE’s work is sufficiently
challenging as it is and is still quite far from that
sort of perfection. Budget impact is not a criterion
when we examine the balance of cost and benefits
within the scope of total resources available; but
we do take into account the implication of sudden
changes in the use of resources (for example, if it
were decided to use a technology that would mean
closing down many hospitals).
 
Unidentified Speaker # 3
 
I really like the idea that Her Majesty sets the dis-
count rates in the UK. Several guidelines recom-
mend the same discount rates for monetary values
and for health gains. In the UK there is a huge dif-
ference. The impact of using such a low discount
rate of 1% to 1.5% for health gains can be tremen-
dous and may mean, for example, that a vaccine
for hepatitis B is available in the UK and not reim-
bursed in the Netherlands. What is the NICE opin-
ion about the desirability and logic of differences
between countries?
 
M. Buxton
 
If the rates genuinely reflect different social values
prevailing in those countries, then it is right that
they be different. We have a political process that
tries to determine what those social values are and
this is the conclusion that Her Majesty’s treasury
has come to. The guidance also says that sensitiv-
ity analysis should be performed on discounting
rates and the Appraisal Committee is very sensi-
tive to those situations where conclusions are highly
dependent on the interest rate chosen. I am satis-
fied with the conclusion that a lower discount rate
for health benefits will tend to favor long-term in-
terventions such as vaccination and health promo-
tion, because this reflects a value I share, and which
more importantly I believe is common within the
UK health care system.
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